Navigation Links
Study of Cell Therapeutics' Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
Date:6/17/2012

SEATTLE, June 18, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced that the University of Washington ("UW") has begun enrolling patients in a randomized phase II study testing the combination of tosedostat with either cytarabine or decitabine for elderly patients with newly-diagnosed acute myeloid leukemia ("AML") or high-risk myelodysplastic syndrome ("MDS"). 

Drs. John Pagel and Elihu Estey, from the University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, are leading the study.

"This is the first study to examine the effects of tosedostat in combination with either cytarabine or decitabine as a first-line therapy.  The study will evaluate how well patients tolerate these combinations, and their effectiveness.  Given that there have been no major advances in treatment of elderly patients with AML, and the results of a previous study of tosedostat by itself in relapsed or refractory patients with AML or MDS showed promising anti-leukemic effects and acceptable tolerability, we are hopeful that this study will demonstrate that tosedostat increases the limited efficacy of these commonly used anti-leukemic agents," Dr. Estey said.

The study's primary objectives are to determine the four-month survival and complete response ("CR") rates of tosedostat in combination with either cytarabine or decitabine in untreated AML or high-risk MDS. The study's secondary objectives are to assess the safety and tolerability of tosedostat in combination with either cytarabine or decitabine, to determine the treatment-related mortality rate (defined as death within the first 30 days of beginning treatment), and to estimate the rates of disease-free survival, one-year survival, and overall survival.   

About the Study

Each arm of the study will enroll up to 20 patients, with the possibility of enrolling an additional five patients each (for a ma
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Positive Clinical Study Results for BSPs HyperQ Technology
2. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
3. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
4. Marshall study shows nanoparticles used as additives in diesel fuels can travel from lungs to liver
5. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
8. Singapore scientists lead human embryonic stem cell study
9. GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly
10. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
11. Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 2014 Follow us on ... young has groomed and nurtured anti-aging products and ... emphasis on appearance maintenance is benefitting the market ... protein obtained from the bacterium, Clostridium Botulinum, which ... relaxation. With cosmetic indications for botulinum toxin ranging ...
(Date:9/22/2014)... 22, 2014 FierceBiotech today announced its ... biotechnology companies of 2014. FierceBiotech editors John Carroll ... this year’s winners. Those selected are identified as ... the industry. , "It's always a lot ... Fierce 15 companies," said Carroll. "This year in particular ...
(Date:9/22/2014)... Sept. 22, 2014  Spherix Incorporated (SPEX) -- an intellectual ... intellectual property, today announced that the United States Patent & ... in the month of September that is part of a ... patent is: USRE45,121 , Application number: US 13/728,867 ... date: Dec 27, 2012 The listed inventors ...
(Date:9/20/2014)... 2014 HealthTronics, Inc. , ... radiology products and services, has signed a distribution ... Clinicon Corporation for its high precision laser ... minimally invasive, mobile, surgical technology—offering more choices for ... agreement, HealthTronics will make available Clinicon’s FDA-cleared SureLase™ ...
Breaking Biology Technology:Strong Demand for Non-Invasive Cosmetic Procedures Drives the Global Botulinum Toxin Market, According to New Report by Global Industry Analysts, Inc. 2Strong Demand for Non-Invasive Cosmetic Procedures Drives the Global Botulinum Toxin Market, According to New Report by Global Industry Analysts, Inc. 3FierceBiotech Announces Annual “Fierce 15” Winners of 2014 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3
... on Thursday announced that three Wisconsin businesses would receive ... Commerce Technology Assistance Grant (TAG) and Technology Venture Fund ... , Functional Biosciences, Inc. , is a ... It will receive a $250,000 TVF loan for work ...
... ads on their round, shiny stomachs as part of "tummy ... To some, this is "desperate branding" in action. , ... spot on the list of branding failures. These projects are ... weird processes. , ,Roy Disney said, "You need branding when ...
... summer. Business slows. Indeed, in Europe, where I find myself ... animation that will last until the first of September. People ... grasp weakens. , ,Or does it? , ,After a rare ... mountain in my inbox and a to-do list that had ...
Cached Biology Technology:A final word on branding 2A final word on branding 3A final word on branding 4A final word on branding 5Leaving it all behind 2
(Date:9/21/2014)... the University of California, San Diego, have developed a ... control the activity of genes based on sequences of ... its application to human embryonic cells in a paper ... , "All of our cells have the same blueprint, ... John Whitaker, lead author of the report. "Skin cells ...
(Date:9/21/2014)... -- Shellfish such as mussels and barnacles secrete very ... ship hulls, even underwater. Inspired by these natural adhesives, ... that could be used to repair ships or help ... new waterproof adhesives, the MIT researchers engineered bacteria to ... proteins as well as a bacterial protein found in ...
(Date:9/19/2014)... today by researchers from several Harvard University labs ... experienced and aspiring researchers with the intellectual raw ... made from soft, flexible materials. , With the ... other advances in manufacturing technology, soft robotics is ... drawn from conventional rigid robot design, but working ...
Breaking Biology News(10 mins):Program predicts placement of chemical tags that control gene activity 2Engineered proteins stick like glue -- even in water 2Engineered proteins stick like glue -- even in water 3Soft robotics 'toolkit' features everything a robot-maker needs 2
... Not only land birds, but also some seabirds, ... example, circumnavigates the earth one and a half times ... about the migratory behaviour of seabirds as compared with ... Planck Institute for Ornithology have studied the migratory behaviour ...
... In a paradigm changing discovery, Plasmodium vivax ( ... historically thought to be resistant to the disease, those who ... red blood cells, according to researchers from Case Western Reserve ... of Health. In a study of more than 600 individuals ...
... experimental oral drug has lowered blood sugar levels and inflammation ... could someday be added to the arsenal of drugs used ... research. The drug consists of a synthetic molecule that ... inhibitory factor, or MIF. This protein is implicated in a ...
Cached Biology News:To the Antarctic or Brazil for new feathers 2To the Antarctic or Brazil for new feathers 3Duffy-negative blood types no longer protected from P. Vivax malaria 2Duffy-negative blood types no longer protected from P. Vivax malaria 3Study points to potential new drug for type 2 diabetes 2Study points to potential new drug for type 2 diabetes 3Study points to potential new drug for type 2 diabetes 4
... The Holten MaxiSafe 2010 Class II ... ergonomical working condition of comfort while ... efficiency and performance.,Refined operator, environment and ... both exhausted and recirculated air.,Bottom filters ...
... Jouan MSC series of Class II ... conditions and certification to the world's ... ensures that the cabinets cannot be ... Natural lighting, low noise and arm ...
... Stand-96 is designed for paramagnetic bead precipitation ... ml PCR plates with no additional accessories. ... in a standard SBS 96-well microplate footprint. ... magnets guarantees easy and fast (as little ...
... circular clear acrylic chamber for complete visibility ... features microprocessor operation for precise mixing capability. ... Carousel rotates at 11 rpm; manufactured ... , Bottle Capacity - four 35 ...
Biology Products: